Trial Profile
A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin (100mg ) and Hepsera (10mg).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Adefovir dipivoxil/lamivudine (Primary) ; Adefovir dipivoxil; Lamivudine
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors GSK
- 19 May 2011 New trial record